Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

Vivos Therapeutics (NASDAQ:VVOS) held its second-quarter earnings conference call on Friday. Below is the complete transcript from the call.

This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/.

The full earnings call is available at https://vivos.com/investors/

Summary

Vivos Therapeutics Inc reported a 35% increase in revenue to $5.2 million for Q2 2026, attributed to an increase in service revenue, despite a decline in product revenue due to strategic shifts.

The company highlighted strategic initiatives, including the acquisition of Sleep Center of Nevada (SCN), expansion of treatment centers, and development of partnerships with cardiology groups in Arizona and Florida.

Vivos Therapeutics Inc aims to achieve positive cash flow by late 2026 or early 2027, with significant growth expected from remote patient monitoring, CPAP services, and EEG testing programs.

Operational highlights include increased patient referrals and expanded capacity at the Henderson facility, supporting the company's strategic growth objectives.

Management acknowledged challenges related to NASDAQ compliance and funding requirements but expressed confidence in meeting these through equity raises and strategic cost management.

Full Transcript

OPERATOR

Good day, everyone, and welcome to the Vivos Therapeutics Inc second quarter 2026 conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow management's remarks. This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days. I would now like to hand the conference over to Brad Ammon, Accounting Officer and former CFO, for introductions and the reading of the safe harbor statement.

Please go ahead.

Roman Franklin, Chief Financial Officer and Principal Financial Officer

Thank you, Ludy. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com. With me on the call today is Kirk Huntsman, Vivos Therapeutics Inc Chairman and Chief Executive Officer, and Roman Franklin, Vivos Therapeutics Inc Chief Financial Officer and Principal Financial Officer. Today we will review the financial results of the second quarter of 2026 as well as more recent developments in Vivos Therapeutics Inc plans for the rest of the year 2026 and beyond.

Following these formal remarks, we will be happy to take questions. I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning future events. Words such as aim, may, could, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates, goal, and variations of such words and similar expressions are intended to identify forward-looking statements.

These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant risks, uncertainties, and contingencies, many of which are beyond the company's control. Actual results, including, without limitation, the results of Vivos Therapeutics Inc growth strategies, operational plans including sales, marketing, distribution, medical sleep provider acquisition and integration, research and development, regulatory initiatives, cost savings plans, and plans to generate revenue, as well as future potential results of operations or operating metrics such as the potential for Vivos Therapeutics Inc to achieve future positive cash flows or profitability and other matters to be addressed by Vivos Therapeutics Inc management in this conference call, may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in other disclosures contained in Vivos Therapeutics Inc filings with the Securities and Exchange Commission, including the risk factors and other disclosures in our Form 10-K for the year ended 12-31-2025 and our other filings with the SEC, including our second quarter 10-Q filed with the SEC today, all of which are or will be accessible on the Investor Relations section of the Vivos Therapeutics Inc website as well as the SEC's website. Except to the extent required by law, Vivos Therapeutics Inc assumes no obligation to update statements as circumstances change. Finally, please be aware that the U.S. Food and Drug Administration has given certain specific Vivos appliances 510(k) clearance to treat mild to severe OSA in adults, with the FDA clearance of certain Vivos Therapeutics Inc products for severe OSA in November of 2023.

Treatment of patients with severe OSA with these specific appliances is no longer needed to be performed off-label at the clinical discretion of the treating doctor and is now an integral part of the Vivos Therapeutics Inc treatment protocol. Treatment of OSA of any severity or any other condition with any other Vivos Therapeutics Inc FDA devices remains at the clinical discretion of the treating doctor. For further information on our results for the three-month period ended June 30, 2026, please see our earnings release which was distributed earlier today, and our quarterly report on Form 10-Q, which is available on the SEC Filings portion of the Investor Relations section of our website. In the second quarter of 2026, Vivos Therapeutics Inc completed its fourth full quarter of activity following our June 10 acquisition in 2025 of the Sleep Center of Nevada (SCN), demonstrating that the pivot in our sales, marketing, and distribution model has taken hold. Revenue increased by approximately $1.3 million, or 35%, to $5.2 million for the three months ended June 30, 2026, compared to $3.8 million for the three months ended June 30, 2025.

The increase in total revenue during the second quarter of 2026 was impacted by an increase of $1.9 million in service revenue and a decrease of a half a million dollars in product revenue to our VIPs. The decrease in product revenue is attributable to a decrease in appliance sales of $1.1 million as a result of our strategic pivot away from VIPs to sleep centers, which is reported as treatment revenue under service revenue, offset by a decrease of a half a million dollars in discounts offered.

The increase in service revenue is attributable to $1.5 million in sleep testing services primarily generated from SCN, and an increase of $800,000 in revenue generated from Vivos Therapeutics Inc treatment launched at two SCN locations, offset by a decrease of $100,000 in VIP enrollment revenue and $100,000 from sponsorship, seminar, and other service revenue. For the six months ended June 30, revenue increased by $3.5 million, or 51%, to $10.3 million compared to $6.8 million for the six months ended last year.

The increase in total revenue during the period was impacted by an increase of $4.4 million in service revenue and a decrease of $900,000 in product revenue. The decrease in product revenue is attributable to a decrease in appliance sales to VIPs of $2.1 million, again due to our strategic pivot, offset by a decrease of $200,000 in discounts offered. The increase in service revenue is attributable to $3.5 million of sleep testing services primarily generated from SCN and an increase of $1.4 million of revenue generated from Vivos Therapeutics Inc treatment to patients launched at two SCN locations, offset by a decrease of $300,000 in VIP enrollment revenue. For the three months ended June 30, 2026, we sold 5,180 oral appliance arches for a total of approximately $1.4 million, a 28% decrease in revenue from the three months ended June 30, 2025 when we sold 4,116 oral appliance arches for a total of $1.9 million. The decrease is directly attributable to a higher volume mix of preformed appliance sales which are lower revenue-generating products when compared to Vivos Therapeutics Inc care appliances.

For the six months ended June 30, 2026, we sold 10,484 oral appliance arches for a total of $2.8 million, a 24% decrease in revenue from the six months ended June 30 of last year when we sold 7,852 arches for a total of $3.7 million. The decrease is directly attributable to a higher volume mix of the preformed appliance sales which are lower revenue-generating products compared to our care devices. As I mentioned earlier, cost of sales increased a half a million dollars, or 29%, to $2.2 million for the three months ended June 30, 2026 compared to $1.7 million for the same period in 2025.

This was primarily attributable to higher costs associated with diagnostic services and patient therapy, including the addition of staff at the Vivos Therapeutics Inc treatment centers. For the six months ended June 30, 2026, cost of sales increased $1.1 million, or 33%, to $4.3 million compared to $3.2 million for the six months ended June 30, 2025. This was primarily related to the higher costs associated with diagnostic services and patient therapy, including additional staff at the Vivos Therapeutics Inc treatment centers.

For the three months ended June 30, 2026, gross profit increased by $800,000 to $3.0 million. This increase was attributable to the increase in revenue of $1.3 million and an increase of cost of sales of a half a million dollars. Gross margin increased to 57% for the three months ended June 30, 2026 compared to 55% for the three months ended June 30, 2025 due to the increase in both revenue and cost of sales. For the six months ended June 30, 2026, gross profit increased by $2.4 million to $6.0 million.

This increase was attributable to the increase in revenue of $3.5 million and an increase in cost of sales of $1.1 million. Gross margin increased to 58% for the six months ended June 30 of this year compared to 53% for the six months ended last year due to the increase in revenue and smaller increase in cost of sales. General and administrative expenses increased $700,000, or 11%, to approximately $7.1 million for the three months ended June 30, 2026 as compared to $6.4 million for the three months ended June 30, 2025.

The primary cause of this increase was $600,000 in salary and wages related to the acquisition of SCN and the opening of Vivos Therapeutics Inc treatment centers, and $300,000 in higher rent expense, offset by a reduction of $200,000 in bad debt and allowances. For the six months ended this year, general and administrative expenses increased $4.8 million, or 42%, to $16.1 million as compared to $11.3 million for the six months ended last year. The primary driver of this increase related to the costs associated with acquiring and integrating SCN and establishing the Vivos Therapeutics Inc treatment centers, including an increase in salaries and related compensation of $3.0 million for additional hiring of staff, an increase of $900,000 for professional fees, and an increase in rent of $600,000, among other costs of $300,000. Sales and marketing expenses decreased $100,000 to $200,000 for the three months ended June 30 of this year compared to $300,000 for the three months ended June 30, 2025. This is attributable in significant part to our focus on reducing costs. Sales and marketing expense decreased $200,000 to $400,000 for the six months ended June 30, 2026 compared to $600,000 for the six months ended June 30, 2025.

This decrease was primarily driven by our decrease in sales and marketing campaigns, lower commissions paid to our employees, digital media services, and reduction in use of marketing supplies due to our pivot. Depreciation and amortization expense increased $200,000 for the three months ended June 30, 2026, and depreciation and amortization expense increased a half a million to $1.0 million for the six months ended June 30, 2026. Depreciation and amortization increased due to assets being placed into service during the period.

Other expense increased $900,000 for the quarter and $2.0 million year to date due to additional interest expense on a note during the three and six months ended June 30, 2026. This was offset by an increase in other income of $300,000 during the three and six months ended June 30, 2026 related to the valuation change in an earnout related to the acquisition of SCN. The financial statements have been prepared in conformity with GAAP, which contemplate continuation of the company as a going concern.

We have incurred losses since inception, including $5.5 million and $5.0 million for the three months ended June 30, 2026 and 2025, respectively, and $13.3 million and $8.9 million for the six months ended June 30, 2026 and 2025, respectively, resulting in an accumulated deficit of $138 million as of June 30, 2026. Net cash used in operating activities amounted to approximately $9.2 million and $7.3 million for the six months ended June 30, 2026 and 2025, respectively.

As of June 30, 2026, we had total liabilities of approximately $28.1 million. As of June 30, 2026, we had approximately $1.8 million in cash and cash equivalents, which will not be sufficient to fund operations and strategic objectives over the next 12 months from the date of issuance of these financial statements without additional financing. These factors raise substantial doubt regarding the company's ability to continue as a going concern. We have implemented cost savings measures in our legacy business that have reduced cash in operations during the first six months of 2025.

Many one-time costs related to the acquisition of SCN were recognized and were not recurring in 2026. As such, we have funded our operations through equity raises in the period ending June 30, 2026 and fiscal year ended December 31, 2025. We were required to obtain additional financing to satisfy our cash needs, including funding the SCN acquisition and increasing our stockholders' equity for Nasdaq compliance purposes, as we seek to increase revenue with a view toward ultimately achieving positive cash flow from operations.

During the six months ended June 30, 2026, the company sold an aggregate of 694,564 ATM shares at an average price of $0.69 per share through the ATM Sales Agreement, resulting in proceeds of approximately a half a million dollars net of commissions under the ATM offering. $2.3 million remain available for future sales as of June 30, 2026. However, the company is not obligated to make any sales under this program. Given that our stockholders' equity at December 31, 2025 and June 30, 2026 was less than $2.5 million, we are presently not in compliance with Nasdaq's Stock Market minimum stockholders' equity requirement.

We are seeking to regain compliance by raising new funding in the form of equity and reducing our costs. However, we will be faced with delisting proceedings which will distract management and cost resources to remedy if we don't remedy the $2.5 million stockholders' equity requirement. In summary, we're seeing significant increases in revenue reflecting the acquisition of SCN, which has now contributed a full year of operations to our results, and partnerships with two additional groups, as well as related treatment revenue from providing patients with OSA treatment options, all of which is extremely encouraging.

We are also seeing higher costs associated with diagnostic services and patient therapy, including addition of staff at the Vivos Therapeutics Inc treatment centers. We believe the strategic move to acquire SCN and to establish other affiliate alliances sets the stage for stronger performance in the upcoming quarters. For more detailed information, I refer you to our earnings release and our full Form 10-Q filed earlier today. And with that, I'll hand the call over to our Chairman and CEO, Kirk Huntsman, to discuss the progress we have made to date on SCN and Vivos Therapeutics Inc.

Kirk Huntsman, Chief Executive Officer

Thank you, Brad. Good afternoon, everyone, and thank you for joining us. I'd like to thank Brad Ammon in particular today for his time. Last six or seven years, Brad has been a key part of our management team, and we're going to miss him. I want to spend a few minutes, if I may, today talking about the operational progress we're making within Sleep Centers of Nevada, something we refer to as SCN, and also discuss several related strategic initiatives because I think it's important for you to understand how these pieces fit together and what they could mean for Vivos Therapeutics Inc over time.

When we first acquired SCN a little over a year ago, we saw an opportunity that went far beyond adding another source of revenue. We saw the potential to build a broader clinical platform around a growing patient population, to provide more services to those patients, to add recurring sources of revenue, expand our capacity and, when clinically appropriate, create additional pathways into the Vivos Therapeutics Inc care model. In the second quarter, we saw that strategy beginning to take shape.

As SCN patient volume continues to grow, we have seen more opportunities to generate revenue both within SCN itself, where most of the diagnostic services are rendered, and also at our strategically located Sleep and Airway Medicine Centers, what we typically refer to as our SAMC centers, where most of the actual treatment takes place. That connection is important. At SCN, medical doctors and nurse practitioners conduct a variety of diagnostic tests and patient consultations and then refer patients out for treatment where medically necessary.

At SAMC, SCN and other independent physician-referred patients with sleep and breathing disorders are provided a full and complete range of treatment options from CPAP to lasers to oral appliances and other adjunctive treatments, including Vivos Therapeutics Inc proprietary rehabilitation and restorative care devices cleared by the FDA to treat all levels of obstructive sleep apnea severity, including severe OSA. Thus, SCN is far more than just a business that simply sits next to Vivos Therapeutics Inc and SAMC.

To ensure optimal clinical outcomes for patients, these two independent groups must fully communicate and support one another. This synergy closes a significant gap in traditional care models throughout sleep medicine today, where there is a significant patient fallout rate due to the roadblocks encountered by patients as they navigate multiple providers and services. I would now like to discuss the clinical and service initiatives to enhance patient care and revenue growth here at Vivos Therapeutics Inc. To further drive top-line revenue growth, over the course of the second quarter Vivos Therapeutics Inc management has launched or expanded several key initiatives across multiple markets. One of the most important clinical initiatives that we're actively pursuing is remote patient monitoring of patients on CPAP. Based on the preliminary data currently available to us, we estimate an addressable population of approximately 16,000 existing CPAP patients from SCN's legacy CPAP patient population.

Under our current eligibility and enrollment estimates, based on industry-standard adoption metrics obtained from our contract service providers, we estimate that approximately 5,000 to 7,500 of those patients could be candidates for enrollment over the next six to 12 months, subject to clinical appropriateness, patient consent, coverage, and enrollment. Based on extensive discussions and negotiations with our service provider, we estimate net revenue per patient per night to come in at between $40 and $50 each.

That gives us a sizable existing patient population from which to build a strong recurring revenue program. To be sure, we are still early in this process, and the pace of adoption will depend on enrollment, reimbursement, implementation, and our ability to execute. But this is exactly the type of opportunity we want to develop within Sleep Centers of Nevada: a recurring revenue service built around a patient population that is already there. Second, separately, we are targeting a phased launch of a wholly owned DME-based CPAP program in early fourth quarter of this year based on preliminary vendor discussions and our current planning assumptions.

If the program reaches the level of scale we are contemplating, we estimate it could generate approximately $150,000 to $250,000 per month in contribution margin. Actual results will depend on successful implementation, patient volumes, reimbursement, vendor economics, and operating execution. If we execute well, this has the potential to add yet another recurring revenue stream to our operations at Sleep Centers of Nevada. Third, we continue to execute and implement our insomnia EEG testing and treatment program at Sleep Centers of Nevada.

Patient encounters, patient tests administered, and revenue generated from this program are all growing rapidly with plenty of upside opportunities remaining. Fourth, we have also expanded and opened our new state-of-the-art Henderson, NV sleep testing and treatment facility, which has effectively more than doubled our production capacity there in Henderson to well over $10 million annually. That expansion gives both Sleep Centers of Nevada and SAMC additional capacity and infrastructure as patient volumes grow.

It's a practical but important piece of this strategy. If we are successful in generating more demand, we also have to be able to serve it. Henderson and its expanded facility give us additional room to do just that and to support more services as the platform continues to develop. Any treatment decision, of course, remains with the independent clinicians that work at these facilities. When clinically appropriate, their evaluations may include consideration of Vivos Therapeutics Inc treatment options consistent with its applicable indications.

So there are two potential benefits. EEG can grow as a standalone service within each of these SAMC centers and Sleep Centers of Nevada, and that can create another clinically appropriate entry point into the broader Vivos Therapeutics Inc care model as those patients begin to receive treatment. Another initiative we've discussed publicly is our contemplated collaboration and partnership opportunities with large cardiology groups in both Arizona and Florida.

We continue to actively pursue those options and expect to finalize our negotiations with both groups in the near future. We expect each of those affiliations to add significantly to our current revenue streams being worked in Colorado, Nevada, and Michigan. Moreover, we expect to extend essentially the same operating model across additional affiliation opportunities that we are pursuing across the country. Based on the operating plan we previously announced, an initial fully staffed sleep optimization team could serve roughly 250 patients per month and, under the assumptions underlying that plan, generate more than $6 million in annual revenue with contribution margins approaching 40% to 50% once fully developed. Number six, we have previously announced our successful launch of a pediatric OSA testing and treatment program across all current markets. Today I'm pleased to announce significant progress in this program. With hundreds of children now receiving treatment and experiencing life-changing effects therefrom, we believe this program is still in its early stages and that there is significant and material upside to enroll and service many more children.

As we continue to expand this program and successfully execute, keep in mind that there are an estimated 10 million children across the United States who suffer from sleep and breathing disorders such as obstructive sleep apnea. Seventh, finally, we continue to refine and fully develop our current opportunities at Sleep Centers of Nevada. At Sleep Centers of Nevada, after considerable work with providers and staff, we are already experiencing a significant uptick in the total referral volume from SCN to SAMC.

Just since the end of the second quarter, we have been seeing three to four times as many patients being referred by SCN physicians and nurse practitioners over to SAMC for treatment. We expect to see production from these referrals begin to impact our financial results in the third quarter. Of course, the realization of these opportunities remains subject to definitive agreements, regulatory requirements, staffing, payer contracting, facility readiness, staff execution, and other operating prerequisites.

However, our deep experience in operating multi-site professional practices across multiple states, as well as our deep experience in Nevada with SCN, gives us a clear competitive advantage as we move forward. Keep in mind that we are still early on in these initiatives and these results are still evolving within our operating model. Actual performance will depend on successful implementation and execution, but the opportunity is straightforward.

The combined effect of these clinical and operational initiatives could be, and is expected to be, material and significant in the weeks and months and quarters ahead. So as we step back and look broadly at these initiatives together and their cumulative effect on our business, I think the strategy for us to achieve positive cash flow and profitability becomes much clearer. More patients from physician referrals give us more opportunities to provide enhanced and recurring services.

More production capacity from our facilities expansion, our providers, and our new collaboration affiliations allow us to serve more patients at higher service levels, and more patient and provider relationships can create, and we expect will create, additional clinically appropriate ways to introduce patients into the core Vivos Therapeutics Inc business ecosystem. That is the model we are building. Based on our current assumptions and subject to successful implementation and scaling, patient enrollment and conversion, reimbursement, vendor economics, available capacity, and operating execution, we see a clear path for Vivos Therapeutics Inc growth initiatives to become cash-flow positive near the end of 2026 or in early 2027 and generate significant positive EBITDA for the company in fiscal 2027. That potential does not depend on just one program working perfectly. It reflects the combined opportunity we see across patient volume growth, remote patient monitoring, CPAP services, expanded capacities, EEG, and our collaborations with cardiology groups in both Florida and Arizona. Now, there's still a lot of work to do.

We have to launch these programs well. We have to enroll the right patients. We have to manage reimbursement and capacities. We have to prove the economics as we go. But that's what this team is focused on. We intend to measure what works, invest behind programs that perform, and be disciplined about how we scale them. And then that brings me back to what I think is most important about our reports here today. The infrastructure that we are building here at Vivos Therapeutics Inc is designed to reinforce the core business, not simply operate alongside of it.

We expect to continue to see more patients with more capacity for generating revenue off of those patients, with more recurring touch points and recurring revenue streams, and more clinically appropriate pathways into treatment for those patients. As we execute, we believe we can create a substantially stronger foundation for future growth across Vivos Therapeutics Inc. I'd like to close by saying that we continue to see a bright future for this company.

Irrespective of what's happened to our stock price in the market, we still believe that this company has a tremendous future. We believe that our technology continues to lead the world in terms of its ability to resolve the conditions of obstructive sleep apnea in both children and adults. And we continue to believe that opportunities to deploy this technology will continue to arise across various platforms. As we do that, this company will emerge as an industry leader, and we believe that it will continue to set the pace for the future of an entire industry of advanced sleep medicine.

And with that, I will close my remarks. Thank you for your time and attention today, and, operator, we'll take a few questions from those who are in attendance today.

OPERATOR

Thank you. And ladies and gentlemen, we will now begin the question and answer session. To ask a question, you may press star followed by the number one on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star followed by the number two. One moment please for your first question. And your first question comes from the line of Yi Chen with HC Wainwright.

Please go ahead.

Kayte, Analyst at HC Wainwright

Hi, this is Kayte on for Yi. Quick follow-up from the call and the release, and you guys have described the Cardiology partnership in Florida and Arizona as approaching finalization. What kind of capital does each one require? And if you can give us a target quarter that would be reasonable to expect revenue to begin.

Roman Franklin, Chief Financial Officer and Principal Financial Officer

So we would expect that each of those will require CapEx of between $800,000 and a million dollars, and we would see them beginning to generate revenue in the first part of the first quarter to second quarter of 2027.

Kayte, Analyst at HC Wainwright

Great. If I have time, a quick follow-up on the insomnia and EEG program. They're cited as a growth driver for kind of the first time. Are you able to define its current quarterly revenue, and how is the reimbursement pathway working for those programs?

Kirk Huntsman, Chief Executive Officer

So let me address the reimbursement pathways. So far, so good with the reimbursements. We're seeing broad participation of insurance payers in the Nevada market, in particular for the EEG testing services, with average reimbursements running around $800, plus or minus. There's quite a broad range there of reimbursement levels, but we're seeing roughly $800 per patient on that score for just the testing. And then the actual treatments. We're just now beginning to refer the patients that have tested positive for insomnia via the EEG.

We begin referring them in, and we don't really have a bead yet on the level of reimbursements, but there's multiple ways in which those—multiple different treatment options, including some of our appliances, our oral appliances, and in particular our Vivos Vita appliance. So there are a number of ways that patients can be treated—traditional ways through CBTI and other traditional methods, as well as some of the methods that we use with our oral appliances.

So I think it's a little early on the treatment reimbursement front, but it is definitely a big win on the reimbursement front. That's a pretty significant level of reimbursement for us as we think about the total volume of patients that could go in, and we expect to be going into this evaluation and testing treatment program for insomnia.

Kayte, Analyst at HC Wainwright

Great. Thank you, guys.

OPERATOR

And I'm showing no further questions at this time. I would like to hand it back to Kirk Huntsman for closing remarks.

Kirk Huntsman, Chief Executive Officer

Thank you, operator. In closing, I'd just like to say that we believe here at Vivos Therapeutics Inc that we have. We continue to see great progress in patient volumes, in margin growth, in actual revenue growth. We see things happening here that are just now beginning to emerge and should be. We've always said that the third quarter of 2026 would probably be the time that we would start to see this show up in the financials. We're starting to see some good positive signs in Q2, but we see a lot greater opportunities for growth and development ahead in Q3.

And as we round the corner going into 2027, which we expect to be a very, very good year for Vivos Therapeutics Inc, we recognize we have some headwinds with respect to sort of our NASDAQ standing and other things, but we are working closely with our investor groups and key constituents to ensure our viability and continuation as best we can on NASDAQ and to comply with all the regulatory requirements that we have before us. So with that, I'll close out today.

We appreciate everyone's support of this company. We continue to feel like we're making a difference in the world doing this. And we appreciate each one of you for your support for Vivos Therapeutics Inc. Thank you very much, and have a great day.

OPERATOR

And this concludes today's conference call. Thank you for your participation. You may now disconnect your lines. Thank you.

Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, there may be errors or omissions in this automated transcription. For official company statements and financial information, please refer to the company's SEC filings and official press releases. Corporate participants' and analysts' statements reflect their views as of the date of this call and are subject to change without notice.